Mosunetuzumab budget impact analysis in patients with recurrent or refractory follicular lymphoma

   Aim. This study aimed to analyze the budget impact of mosunetuzumab use in patients with relapsed or refractory follicular lymphoma in the third and subsequent lines of therapy.

   Materials and methods. Budget impact analysis, sensitivity analysis.

   Results. The target population size was 340 people. Analysis of the costs of drug therapy for the third and subsequent lines demonstrated a wide range of costs: the maximum costs are associated with the use of mosunetuzumab (RUB 6,296,060.33, 8 cycles and RUB 11,906,411.12, 17 cycles), and the minimum costs are associated with the use of the GDP regimen without rituximab (RUB 31,390.80). The total costs for 1 year of modeling the current practice for all types of therapy amounted to RUB 891,446,565.79. In current practice, the main share of costs is attributed to the drug duvelisib (47.4 %), followed by the regimen ibrutinib+/-R (25.1 %) and R-B (6.1 %). More than 70 % of the current practice costs are spent on drugs that do not have an official indication for use. The total cost of 1 year of modeling amounted to RUB 693,639,708.26. Over the specified modeling period, the main share of costs was attributed to the following regimens: ibrutinib+/-R (32.3 %) and mosunetuzumab monotherapy (27.2 %). Budget impact analysis demonstrated that the use of mosunetuzumab will save 22.2 % or RUB 197,806,857.54 over 1 year and will allow for additional treatment with mosunetuzumab to 31 new patients. Sensitivity analysis of the budget impact analysis results demonstrated that the model is sustainable to changes in all initial parameters, even within the proposed option of transferring all patients from duvelisib to mosunetuzumab monotherapy will lead to a savings in current costs (2.9 %).

   Conclusions. The use of mosunetuzumab as a 3^rd and subsequent line therapy in adult patients with relapsed or refractory follicular lymphoma is an economically feasible approach within the Russian healthcare framework.

1. Clinical guidelines. Follicular lymphoma / Association of Oncologists of Russia, National Society of Pediatric Hematologists, Oncologists, Russian Society of Oncohematology, Association for the Promotion of Hematology, Transfusiology and Bone Marrow Transplantation "National Hematology Society". Ministry of Health of the Russian Federation, 2024. [Internet]. (In Russ.) [доступ от 12. 06. 2025]. Доступ по ссылке https://cr.minzdrav.gov.ru/preview-cr/151_2.

2. Zelenetz AD, et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 2.2024 — April 30, 2024.

3. Tumyan GS. Follicular lymphoma. Clinic, diagnosis, treatment textbook, [specialty FGOS HE "Oncology" 08/31/57+DPP module 2]. GS Tumyan, LG Babicheva, IV Poddubnaya; Ministry of Health of the Russian Federation, Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education. Moscow : Ekon-Inform, 2020. (In Russ.) ISBN 978-5-907233-74-4.

4. Casulo C. Upfront identification of high-risk follicular lymphoma. Hematol Oncol. 2021 Jun;39 Suppl 1:88-93. doi: 10.1002/hon.2852.

5. Babicheva LG, Poddubnaya IV. First-line therapy of indolent non-Hodgkin's lymphoma in routine clinical practice. Journal of Modern Oncology. 2020;22(2):119–125. (In Russ.) doi: 10.26442/18151434.2020.2.200125.

6. Babicheva LG, Tumian GS, Kravchenko SK. Follikuliarnaia limfoma. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed by. IV Poddubnoi, VG Savchenko. 2018; p. 43-52 (In Russ.)

7. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013 Aug 8;122(6):981-7. doi: 10.1182/blood-2013-03-491514.

8. Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019 Feb;184(4):660-663. doi: 10.1111/bjh.15149.

9. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z.

10. Casulo C, Larson MC, Lunde JJ, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022 Apr;9(4):e289-e300. doi: 10.1016/S2352-3026(22)00033-3

11. Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol. 2018 Sep;31(3):251-261. doi: 10.1016/j.beha.2018.07.008.

12. Krylova YaV, Kondakova EV, Gavrilenko AN, et al. Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study. Onkogematologiya = Oncohematology 2024;19(3):153-8. (In Russ.) doi: 10.17650/1818-8346-2024-19-3-153-158.

13. HIGHLIGHTS OF PRESCRIBING INFORMATION. LUNSUMIO™ (mosunetuzumab-axgb) injection, for intravenous use Initial U.S. Approval: 2022 [Internet]. [cited 2025 Jun 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf

14. Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802.

15. Ferl GZ, Reyes A, Sun LL, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018 May;11(3):296-304. doi: 10.1111/cts.12535.

16. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7.

17. Compassionate use treatment with mosunetuzumab for patients with relapsed/refractory follicular lymphoma (r/r FL) (AG42295). Guidance Document, version 3.0. 2021.

18. Cheah CY, Bartlett NL, Assouline S, et al. P1124: Mosunetuzumab retreatment is effective and well-tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Hemasphere. 2022 Jun 23;6(Suppl):1014-1015. doi: 10.1097/01.HS9.0000847364.49527.45.

19. Bartlett NL, Sehn LH, Matasar MJ, et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal phase II study. Blood:140(Suppl 1):1467-1470. doi: 10.1182/blood-2022-157691.

20. Shadman M, Bartlett NL, Schuster SJ, et al. Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study. ASH 2024. Abstract P4407

21. Sehn LH, Bartlett NL, Matasar M, et al. P1078: Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: updated analysis of a pivotal phase II study. Hemasphere. 2023 Aug 8;7(Suppl):e36694eb. doi: 10.1097/01.HS9.0000971208.36694.eb.

22. Kanters S, Ball G, Kahl B, et al. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma : a systematic literature review and meta-analysis. BMC Cancer. 2023 Jan 23;23(1):74. doi: 10.1186/s12885-023-10546-6.

23. Guidelines for assessing the impact on the budget as part of the implementation of the program of state guarantees for free medical care for citizens. — Moscow: 2018. (In Russ.)

24. Guidelines for conducting a comparative clinical and economic assessment of a medicinal product. Approved by Order No. 242-od. FGBU «CEKKMP» MoH Russia, dated December 29, 2018. Moscow: 2018. (In Russ.)

25. Guidelines for the use of mathematical modeling in clinical and economic studies and studies using budget impact analysis. Approved by Order No. 189-od. FGBU «CEKKMP» MoH Russia, dated December 30, 2019, Moscow: 2019. (In Russ.)

26. Poddubnaya IV, Babicheva LG. Diffuse large B-cell lymphoma and follicular lymphoma: problem state in Russia. Journal of Modern Oncology. 2024;26(2):140–148. (In Russ.) doi: 10.26442/18151434.2024.2.202798.

27. Guidelines for calculating costs in clinical and economic studies of medicinal products. Approved by Order No. 185-od dated December 29, 2017, FGBU «CEKKMP» MoH Russia, 2017. (In Russ.)

28. Clinical guidelines. Aggressive non-follicular lymphomas — diffuse large B-cell lymphoma, high-grade B-cell lymphoma with c-MYC and BCL2/BCL6 gene rearrangement, primary mediastinal B-cell lymphoma 28. Clinical guidelines. Aggressive non-follicular lymphomas — diffuse large B-cell lymphoma, high-grade B-cell lymphoma with c-MYC and BCL2/BCL6 gene rearrangement, primary mediastinal B-cell lymphoma, mediastinal gray zone lymphoma, Burkitt lymphoma, plasmoblastic lymphoma / Association of Oncologists of Russia, National Hematology Society, National Society of Pediatric Hematology, lymphoma, mediastinal gray zone lymphoma, Burkitt's lymphoma, plasmoblastic lymphoma / Association of Oncologists of Russia, National Hematology Society, National Society of Pediatric Hematologists, Oncologists, Russian Society of Oncogematologists // Ministry of Health of the Russian Federation, 2024. [Internrt]. (In Russ.) Доступно по: https://cr.minzdrav.gov.ru/preview-cr/129_3. Ссылка активна на 12. 06. 2025.

29. Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915.

30. Leonard JP, Trneny M, Izutsu K, et al; AUGMENT Trial Investigators. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010.

31. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960.

32. Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0.

33. Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3.

34. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327.

35. Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853.

36. Bachy E, Houot R, Feugier P, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood. 2022 Apr 14;139(15):2338-2346. doi: 10.1182/blood.2021013526.

37. Weide R, Feiten S, Friesenhahn V, et al. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma. 2013 Aug;54(8):1640-6. doi: 10.3109/10428194.2012.747679.

38. Moccia AA, Hitz F, Hoskins P, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leuk Lymphoma. 2017 Feb;58(2):324-332. doi: 10.1080/10428194.2016.1193852.

39. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol. 2003;14 Suppl 1:i11-6. doi: 10.1093/annonc/mdg703.

40. Bagova MO. Magomedova AU, Kravchenko SK, et al. Comparative assessment of efficacy and toxicity of R-DA-EpOCH and R-mNHl-BFM-90 induction courses in the treatment of patients with diffuse large B-cell lymphoma with poor prognostic factors in a randomized multicenter clinical trial “DlBCl-2015”. Onkogematologiya = Oncohematology. 2021;16(3):86-94. (In Russ.) doi: 10.17650/1818-8346-2021-16-3-86-94.

41. Bond DA, Wei L, Yildiz V, et al. Combination of the PD-1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B-cell Lymphoma: Results from a Phase I/II Study. Hematological Oncology. 2023;41(S2):597-598. doi: 10.1002/hon.3164_447.

42. Bertino JR, et al. Accelerated R-COP: A Pilot Study for the Treatment of Follicular Lymphoma. Blood. 2005;106 (11):4747. doi: 10.1182/blood.V106.11.4747.4747.

43. State Register of Maximum Selling Prices. [Internet]. (In Russ.) Доступно по: http://grls.rosminzdrav.ru/PriceLims.aspx. Ссылка активна на 12. 06. 2025.

44. The Tax Code of the Russian Federation (Part two) dated 08/05/2000 No. 117–ФЗ (as amended on 04/20/2021) (as amended and supplemented, intro. effective from 05/20/2021). Article 164. Tax rates. Item 2. 2021. [Internet]. (In Russ.) Доступно по: http://www.consultant.ru/document/cons_doc_LAW_28165/35cc6698564adc4507baa31c-9cfdbb4f2516d068/. Ссылка активна на 12. 06. 2025.

45. Market research "Current practice of diagnosis and treatment of recurrent/refractory FL". MarConsult, April 2023 (report provided by the Customer). (In Russ.)

46. Lin SW, Shapouri S, Parisé H, et al. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. Pharmacoeconomics. 2024 May;42(5):569-582. doi: 10.1007/s40273-024-01358-y.

47. Matasar M, Sanchez Alvarez J, et al. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2024 Jan-Dec;27(1):766-776. doi: 10.1080/13696998.2024.2352820.

48. Bellone M, Sabinot A, D'Arpino A, et al. A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy. Glob Reg Health Technol Assess. 2024 Dec 9;11:239-247. doi: 10.33393/grhta.2024.3170.